Renalytix PLC Publication of Annual Report 2021 & Notice of AGM (0262T)
19 Noviembre 2021 - 10:43AM
UK Regulatory
TIDMRENX
RNS Number : 0262T
Renalytix PLC
19 November 2021
Renalytix plc
("Renalytix" or the "Company")
Publication of Annual Report 2021
and Notice of 2021 Annual General Meeting
LONDON and SALT LAKE CITY, November 19, 2021 - Renalytix plc
(NASDAQ: RNLX) (LSE: RENX) announces that the Annual Report for the
year ended 30 June 2021 and the Notice of the 2021 Annual General
Meeting ('AGM') have now been published on the Company's website in
accordance with AIM Rule 20:
https://investors.renalytix.com/news-and-events/documents-and-presentations
The 2021 Annual Report and the Notice of AGM will be posted to
shareholders who have not consented to receive electronic
communications.
The AGM will be held in-person on 17 December 2021 at 3.00p.m.
(GMT) at 6 Stratton Street Mayfair, London W1J 8LD.
Any Shareholder intending to attend will need to register first
by contacting Walbrook PR via email at renalytix@walbrookpr.com or
by telephone at +44 (0)20 7933 8790. If you are planning to attend
in-person, please provide details for track and trace to Walbrook
PR.
The Directors consider that the proposed resolutions contained
in the Notice of Annual General Meeting are in the best interests
of the Company and shareholders as a whole and unanimously
recommend that you vote in favour of them, as they intend to do in
respect of their own shareholdings.
Proxy voting
You will not receive a hard copy form of proxy for the Annual
General Meeting in the post. Instead, you will be able to vote
electronically using the link www.signalshares.com. You will need
to log into your Signal Shares account, or register if you have not
previously done so. To register you will need your Investor Code,
this is detailed on your share certificate or available from our
Registrar, Link Group.
You may request a hard copy form of proxy directly from Link
Group at shareholderenquiries@linkgroup.co.uk or on +44 (0)371 664
0300. Calls are charged at the standard geographic rate and will
vary by provider. Calls outside the United Kingdom will be charged
at the applicable international rate. Lines are open between 09:00
- 17:30 (GMT), Monday to Friday excluding public holidays in
England and Wales. A proxy may also be appointed by CREST members,
by using the CREST electronic proxy appointment service, further
details of which are set out in the Notice. Proxy votes and
electronic votes must be received by no later than 3 p.m. (GMT) on
15 December 2021.
For further information, please contact:
Renalytix plc www.renalytix.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker Tel: 020 7710 7600
)
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker) Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Applegarth Mob: 07980 541 893 / 07584
391 303
CapComm Partners Tel: 415-389-6400 or investors@renalytix.com
Peter DeNardo
About Kidney Disease
Kidney disease is now recognized as a public health epidemic
affecting over 850 million people globally. The Centers for Disease
Control and Prevention (CDC) estimates that 15% of US adults, or 37
million people, currently have chronic kidney disease (CKD).
Further, the CDC reports that 9 out of 10 adults with CKD do not
know they have it and one out of two people with very low kidney
function who are not on dialysis do not know they have CKD.(1)
Kidney disease is referred to as a "silent killer" because it often
has no symptoms and can go undetected until a very advanced stage.
Each year kidney disease kills more people than breast and prostate
cancer. Every day, 13 patients in the United States die while
waiting for a kidney transplant.
About KidneyIntelX
KidneyIntelX, is a first-of-kind solution that enables
early-stage diabetic kidney diseases (DKD) progression risk
assessment by combining diverse data inputs, including validated
blood-based biomarkers, inherited genetics, and personalized
patient data from electronic health record, or EHR, systems, and
employs a proprietary algorithm to generate a unique patient risk
score. This patient risk score enables prediction of progressive
kidney function decline in CKD, allowing physicians and healthcare
systems to optimize the allocation of treatments and clinical
resources to patients at highest risk.
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and
leader in the new field of bioprognosis(TM) for kidney health. The
company has engineered a new solution that successfully enables
early-stage chronic kidney disease, progression risk assessment.
The Company's lead product, KidneyIntelX, has been granted
Breakthrough Designation by the U.S. Food and Drug Administration
and is designed to help make significant improvements in kidney
disease prognosis, transplant management, clinical care, patient
stratification for drug clinical trials, and drug target discovery
(visit www.kidneyintelx.com ). For more information, visit
www.renalytix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSFFAFMUEFSEDF
(END) Dow Jones Newswires
November 19, 2021 11:43 ET (16:43 GMT)
Renalytix (LSE:RENX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Renalytix (LSE:RENX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
